文章：

代谢功能障碍相关脂肪性肝病与肾癌风险增加相关：一项全国性研究

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study

原文发布日期：15 September 2024

DOI: 10.3390/cancers16183161

类型: Article

开放获取: 是

英文摘要：

Background: This study investigated the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and Kidney Cancer Risk, as the incidence of both diseases gradually increases owing to metabolic health issues.Methods: Participants (aged 20–79) undergoing a national health examination between 2009 and 2010 were monitored for new-onset kidney cancer. The MASLD spectrum was classified as non-MASLD, MASLD, or MASLD with increased alcohol uptake (MetALD). Kidney Cancer Risk associated with the MASLD spectrum was estimated using multivariate Cox proportional hazard models. Age- and sex-stratified analyses were also performed.Results: Among 8,829,510 participants (median follow-up 13.3 years), the proportion of non-MASLD, MASLD, and MetALD was 64.9%, 30.3%, and 4.7%, respectively, with newly developed kidney cancer in 17,555 participants. Kidney cancer was significantly increased with MASLD (adjusted hazard ratio [aHR] 1.51, 95% confidence interval [CI] 1.46–1.56) and MetALD (aHR 1.51, 95% CI 1.42–1.61), compared with the non-MASLD group. Kidney Cancer Risk was the highest among young populations (aHR 1.93, 95% CI 1.77–2.11 for MASLD and aHR 1.91, 95% CI 1.65–2.22 for MetALD), according to stratification analysis. Furthermore, the cumulative relationship between metabolic dysfunction and Kidney Cancer Risk was confirmed across all MASLD spectra.Conclusions: Our study highlights the positive association between MASLD and Kidney Cancer Risk, emphasizing a comprehensive approach to metabolic health. This also serves as a call to devote closer attention to the metabolic health of younger patients.

摘要翻译： 

背景：本研究旨在探讨代谢功能障碍相关脂肪性肝病（MASLD）与肾癌风险之间的关联，鉴于两者发病率因代谢健康问题而逐渐上升。 方法：对2009年至2010年间接受全国健康检查的参与者（年龄20-79岁）进行新发肾癌的监测。MASLD谱系分为非MASLD、MASLD及酒精摄入增加的MASLD（MetALD）。采用多变量Cox比例风险模型评估与MASLD谱系相关的肾癌风险，并进行了年龄和性别分层分析。 结果：在8,829,510名参与者中（中位随访时间13.3年），非MASLD、MASLD和MetALD的比例分别为64.9%、30.3%和4.7%，其中17,555名参与者新发肾癌。与非MASLD组相比，MASLD组（调整后风险比[aHR] 1.51，95%置信区间[CI] 1.46–1.56）和MetALD组（aHR 1.51，95% CI 1.42–1.61）的肾癌风险显著增加。分层分析显示，年轻人群的肾癌风险最高（MASLD组aHR 1.93，95% CI 1.77–2.11；MetALD组aHR 1.91，95% CI 1.65–2.22）。此外，在所有MASLD谱系中均证实了代谢功能障碍与肾癌风险之间的累积关系。 结论：本研究强调了MASLD与肾癌风险之间的正相关关系，呼吁对代谢健康采取综合管理策略，并需更加关注年轻患者的代谢健康状况。

原文链接：

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study